Screening of a chemical library reveals novel PXR-activating pharmacologic compounds
Graphical abstract
Introduction
The pregnane X receptor (PXR) gene belongs to the nuclear hormone receptor (NHR) superfamily (Blumberg et al., 1998, Kliewer et al., 1998). The PXR product, similar to several other NHRs, functions as an endobiotic- and xenobiotic-sensing transcription factor capable of regulating the metabolism and disposition of recognized compounds (Bertilsson et al., 1998, Goodwin et al., 1999, Kliewer et al., 1998, Lehmann et al., 1998, Waxman, 1999). This receptor recognizes a broad spectrum of structurally diverse compounds, including endogenous metabolites such as bile acids (Staudinger et al., 2001) and estrogens (Kliewer et al., 1998); environmental toxins such as organochlorines (Mikamo et al., 2003), phthalate esters (Hurst and Waxman, 2004), and mycotoxins (Ratajewski et al., 2011); and different pharmacologic compounds including rifampicin, dexamethasone, clotrimazole, phenobarbital, RU486, and SR 12,813 (Moore et al., 2000). PXR is recognized as one of the master regulators of liver metabolism, especially liver-based processes of xenobiotic transformation (Francis et al., 2003). Among the genes that are regulated by PXR are multiple genes that encode enzymes, such as CYP3A4 (Lehmann et al., 1998), CYP2B6 (Goodwin et al., 2001), CYP2C9 (Gerbal-Chaloin et al., 2002), CYP7A1 (Staudinger et al., 2001), UGTs (Gardner-Stephen et al., 2004), SULTs (Duanmu et al., 2002); and transporters, such as ABCB1 (Geick et al., 2001, Synold et al., 2001) and OATP2 (Staudinger et al., 2001), that are involved in xenobiotic metabolism and disposition. Among many PXR regulated genes that are involved in drug metabolism CYP3A4 is of special interest because its product is responsible for metabolism of up to 37% of the hepatically cleared drugs (Zanger et al., 2008). Interactions between pharmacologic compounds and PXR are important because recognition by PXR may significantly increase the rate of transformation of other xenobiotics in the liver, resulting in drug-to-drug interactions (Fuhr, 2000, Kliewer et al., 1998, Lehmann et al., 1998). Thus, the ability to interact with PXR is an important feature of a pharmacologic compound that significantly increases the risk of this compound’s interactions with other drugs. There are many examples of compounds capable of mediating PXR-dependent drug-to-drug interaction processes, which have been determined by in vitro studies and studies employing animal models (Luo et al., 2002, Xie and Evans, 2002). There are also published clinical observations supporting the importance of PXR-mediated drug-to-drug interactions, such as interactions between rifampicin and antivirals, including efavirenz (Lopez-Cortes et al., 2002) and nevirapine (Ribera et al., 2001), and the antihypertensive drug verapamil (Fuhr, 2000); or interactions between St. John’s wort extracts and the HIV protease inhibitor indinavir (Piscitelli et al., 2000), the immunosuppressant cyclosporin (Ruschitzka et al., 2000), and the antineoplastic agent irinotecan (Yang et al., 2010). An assessment of the overall risk of such PXR-dependent drug-to-drug interactions may be based on the observation that approximately 2% of currently registered drugs are capable of inducing the expression of the CYP3A4 (Smith, 2000) gene, which is known to be predominantly regulated by a PXR-dependent pathway. Thus, the hypothesis that PXR-mediated changes are important for clinically relevant drug-to-drug interactions (DDI) is broadly accepted and supported by experimental and clinical data. Additional clinically relevant aspects of the interactions between pharmacologic compounds and PXR that have emerged from recent reports include the PXR-mediated induction of xenobiotic-metabolizing enzymes and transporters in cancer cells, which may lead to the development of drug-resistant phenotypes (Chen et al., 2007, Mensah-Osman et al., 2007).
The interactions of numerous chemical compounds with the PXR molecule have been investigated using different experimental and theoretical models. One of the striking features of this receptor is its ability to bind structurally diverse molecules. Two model ligands frequently employed in studies of PXR function are SR 12,813 and rifampicin. These compounds, which differ significantly in molecular weight (504 and 822, respectively), have been used to obtain crystals of the ligand-binding domain of PXR (Chrencik et al., 2005, Watkins et al., 2001). Crystallographic studies have resulted in a hypothesis explaining the structural basis of the ligand promiscuity of PXR, linking this feature of PXR to the flexible structure of the PXR ligand-binding domain, which results from the presence of polypeptide loops that acquire disorderly structures upon ligand binding (Chrencik et al., 2005, Watkins et al., 2001). This mechanism of ligand-receptor interaction may explain the difficulties in developing predictive models for the relationship between the structures of molecules and their PXR-binding capacities. Although several such models have shown significant correlations between selected molecular descriptors and PXR binding or transactivation, these models alone do not suffice for screening drug candidates in the development process (Sinz et al., 2008). Therefore, the prediction of potential PXR-mediated DDI interactions requires additional experimental data, which could be provided by high-throughput methods of detecting PXR activation. Among the methods developed and proposed for implementation as a tool to predict a drug candidate’s potential to activate PXR is the detection of the direct binding of a tested molecule to a recombinant PXR protein (Jones et al., 2000, Zhu et al., 2004). A potential downside of this approach is the difficulty in distinguishing agonists from antagonists. In vitro cell-based assays detecting the transactivation of PXR using reporter gene technique provide additional information on the functional consequences of interactions of tested compounds with PXR. These methods frequently employ the transient cotransfection of a hepatocyte-like cell line with PXR-expressing and PXR-dependent reporter gene constructs (Goodwin et al., 1999, Kliewer et al., 1998, Luo et al., 2004, Sinz et al., 2006, Zhu et al., 2004). Alternatively, a cell line expressing endogenous PXR could be stably transfected with a PXR-dependent reporter gene transgene to obtain a reporter cell line. We previously used such an approach to develop the reporter cell line nhrtox-hepg2, which was employed for the screening of mycotoxins and experimental antineoplastic compounds for their capability to activate PXR (Ratajewski et al., 2011, Niemira et al., 2013). Now we have employed this reporter cell line to screen a 1120-compound chemical library consisting predominantly of pharmacologic substances. As will be shown in this report, a series of screening experiments has detected a number of PXR activators, including novel, previously unreported PXR-transactivating compounds that are capable of upregulating CYP450 expression in HepG2 cells.
Section snippets
Chemicals
The Prestwick Chemical Library, which contains 1120 chemicals, was purchased from Prestwick Chemical (Illkirch, France). Substances for the second and third stages of screening were obtained from Sigma–Aldrich (St. Louis, MO, USA), except for hydrastine and bromoperidol, which were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
Cell culture
The HepG2 (hepatocellular carcinoma) cell line was obtained from the ATCC (Manassas, USA) and was maintained under standard conditions in Dulbecco’s Modified
Results
In the first round of screening, nhrtox-hepg2 cells were exposed to 1120 compounds from the Prestwick chemical library, each at a concentration of 1 μg/ml. As shown in Fig. 1, 59 compounds exhibited increased PXR-dependent luciferase expression to a level greater than 150% of the expression in the untreated control cells. In the next round of screening, all the compounds that were positive in the first round of screening were tested for PXR transactivation and cytotoxicity at increasing
Discussion
We employed human hepatoma HepG2 cell line-derived reporter cells (nhrtox-hepg2) to screen for novel PXR-transactivating pharmacologic compounds. Of 38 compounds that mediated PXR transactivation in a dose-response fashion and at non-cytotoxic concentrations, 19 also caused a significant upregulation of CYP3A4 expression (Fig. 2, Table 1, Table 2). Usage of relative induction of mRNA for CYP3A4 as a marker for PXR agonist was previously validated using primary human hepatocytes (Fahmi et al.,
Funding
This work was supported by a grant from the European Regional Development Fund (POIG.01.01.02-10-107/09) under the Operational Programme Innovative Economy.
Conflict of interest
The authors declare no competing financial interest.
References (73)
- et al.
Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin
J. Biol. Chem.
(2001) - et al.
Transcriptional regulation of CYP2C9 gene: role of glucocorticoid receptor and constitutive androstane receptor
J. Biol. Chem.
(2002) - et al.
Environmental phthalate monoesters activate pregnane X receptor-mediated transcription
Toxicol. Appl. Pharmacol.
(2004) - et al.
A practical view of ‘druggability’
Curr. Opin Chem. Biol.
(2006) - et al.
An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway
Cell
(1998) - et al.
Endocrine disruptors induce cytochrome P450 by affecting transcriptional regulation via pregnane X receptor
Toxicol. Appl. Pharmacol.
(2003) - et al.
Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands
J. Biol. Chem.
(2000) - et al.
Pregnane X receptor dependent up-regulation of CYP2C9 and CYP3A4 in tumor cells by antitumor acridine agents, C-1748 and C-1305, selectively diminished under hypoxia
Biochem. Pharmacol.
(2013) - et al.
Indinavir concentrations and St. John’s wort
Lancet
(2000) - et al.
Aflatoxins upregulate CYP3A4 mRNA expression in a process that involves the PXR transcription factor
Toxicol. Lett.
(2011)
Acute heart transplant rejection due to Saint John’s wort
Lancet
Induction and drug development
Eur. J. Pharm. Sci.
P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR
Arch. Biochem. Biophys.
Pharmaceutical use of mouse models humanized for the xenobiotic receptor
Drug Discov. Today
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Lancet Oncol.
Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays
J. Biomol. Screen.
PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide
Eur. J. Pharm. Sci.
Old and new antirheumatic drugs and the risk of hepatotoxicity
Ther. Drug Monit.
ChemMine tools: an online service for analyzing and clustering small molecules
Nucleic Acids Res.
Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction
Proc. Natl. Acad. Sci. U. S. A.
SXR, a novel steroid and xenobiotic-sensing nuclear receptor
Gene Dev.
Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid
Eur. J. Clin. Pharmacol.
Clinical pharmacokinetics of mycophenolate mofetil
Clin. Pharmacokinet.
Molecular identification number for substructure searches
J. Chem. Inf. Comput. Sci.
Chemically intuitive molecular index
Quant. Struct.-Acta Relat.
Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways
Drug Metab. Dispos.
Human pregnane X receptor and resistance to chemotherapy in prostate cancer
Cancer Res.
In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression
Transplantation
Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin
Mol. Endocrinol.
Absorption of kaempferol from endive, a source of kaempferol-3-glucuronide, in humans
Eur. J. Clin. Nutr.
Effects of dexamethasone on aryl (SULT1A1)- and hydroxysteroid (SULT2A1)-sulfotransferase gene expression in primary cultured human hepatocytes
Drug Metab. Dispos.
Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes
Drug Metab. Dispos.
Nuclear receptors and the control of metabolism
Annu. Rev. Physiol.
Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans
Clin. Pharmacokinet.
Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression
Drug Metab. Dispos.
Cited by (23)
QSAR analysis for pyrimidine and pyridine derivatives as RIPK2 (receptor interacting protein kinase 2) inhibitors
2023, Journal of the Indian Chemical SocietyDiscrepancy in interactions and conformational dynamics of pregnane X receptor (PXR) bound to an agonist and a novel competitive antagonist
2022, Computational and Structural Biotechnology JournalCitation Excerpt :In this regard, regulatory agencies, including the European Medicines Agency (EMA) [9] and the United States Food and Drug Administration (FDA) [10], have introduced in vitro assays for PXR activation and in vivo CYP expression levels in their pipelines for evaluation of drug safety. In addition to its role in small molecule metabolism, PXR is involved in regulation of diverse cellular processes including energy homeostasis, cell proliferation and inflammation [11,12]. PXR expression adapts to (patho) physiological [13] and environmental stimuli [14].
Deciphering structural bases of intestinal and hepatic selectivity in targeting pregnane X receptor with indole-based microbial mimics
2021, Bioorganic ChemistryCitation Excerpt :Thus far the indole metabolite medicinal chemistry has mainly focused on developing indole-pharmacophore based drugs, however, not specifically as PXR ligands [10]. Indeed, while some databases have few indole-like structures that do bind and activate PXR [11–14], there is no formal or focused effort defining the structure–activity relationships (SAR) of a focused library built around bis-indole motif. Overall, it is clear that engaging the appropriate activation of PXR in the setting of colitis using drug-like ligands that are essentially non-toxic to the host and have a locoregionally (intestine-specific) restricted pharmacology (no systemic exposure), will be the ideal way to create a paradigm shift in IBD therapeutics.
Enzyme Regulation
2018, Comprehensive Toxicology: Third EditionFish as a model to assess chemical toxicity in bone
2018, Aquatic ToxicologyCitation Excerpt :For example, the Cignal Reporter Assays (QIAGEN; www.sabiosciences.com) enables the screening of up to 45 different signaling pathways simultaneously, and the Transcription Factor (TF) Activation Profiling Plate Arrays (Signosis; www.signosisinc.com) can monitor the activity of up to 96 transcription factors. Although large scale screening methodologies are interesting from a pharmaceutical and ecotoxicological point of view (Ratajewski et al., 2015), particular limitations exist in relation to the use of species-specific TF probes (Signosis assay) or binding sites (QIAGEN assay), which may not reflect accurately the potential activation/inhibition of related pathways in other species. This is the case for Pxr, as previously mentioned due to a highly divergent evolution, showing significant differences in ligand specificity across species (Ekins et al., 2008).
Mechanisms of xenobiotic receptor activation: Direct vs. indirect
2016, Biochimica et Biophysica Acta - Gene Regulatory MechanismsCitation Excerpt :One HTS assay developed for PXR used time-resolved FRET between fluorescent-tagged PXR LBD and coactivator SRC-1 to identify PXR activators, similar to those used in CAR activator screening [93]. Stable HepG2 cell lines expressing a reporter plasmid have also been developed for HTS and successfully used to identify PXR activators, but again, these immortalized cell lines do not exhibit metabolic capacity and therefore, will not necessarily predict physiologically-relevant PXR activators, showing the need for screening in human primary hepatocytes [94]. Although classical understanding of PXR activation necessitates that a ligand must be bound to impart transcriptional activity, emerging evidence indicates that the status of PXR activation can be influenced by different cellular signaling pathways.